scholarly journals Effect of folic acid supplementation in pregnancy on gene specific DNA methylation in the child: evidence from a randomised controlled trial

2016 ◽  
Vol 75 (OCE3) ◽  
Author(s):  
A. Caffrey ◽  
H. McNulty ◽  
C. Walsh ◽  
R. Irwin ◽  
K. Pentieva
BMJ Open ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. e040416
Author(s):  
Dian Sulistyoningrum ◽  
Tim Green ◽  
Debbie Palmer ◽  
Thomas Sullivan ◽  
Simon Wood ◽  
...  

IntroductionTaking folic acid containing supplements prior to and during early pregnancy reduces the risk of neural tube defects. Neural tube defects occur prior to 28 days postconception, after which, there is no proven benefit of continuing to take folic acid. However, many women continue to take folic acid containing supplements throughout the pregnancy. At higher intakes, folic acid is not converted to its active form and accumulates in circulation as unmetabolised folic acid (UMFA). Recently, concerns have been raised about possible links between late gestation folic acid supplementation and childhood allergy, metabolic disease and autism spectrum disorders. We aim to determine if removing folic acid from prenatal micronutrient supplements after 12 weeks gestation reduces circulating levels of maternal UMFA at 36 weeks gestation.Methods and analysisThis is a parallel-design, double-blinded randomised controlled trial. Women ≥12 and <16 weeks’ gestation with a singleton pregnancy and able to give informed consent are eligible to participate. Women (n=100; 50 per group) will be randomised to receive either a micronutrient supplement containing 0.8 mg of folic acid or a micronutrient supplement without folic acid daily from enrolment until delivery. The primary outcome is plasma UMFA concentration at 36 weeks gestation. Secondary outcomes include red blood cell folate and total plasma folate concentration. We will assess whether there is a difference in mean UMFA levels at 36 weeks gestation between groups using linear regression with adjustment for baseline UMFA levels and gestational age at trial entry. The treatment effect will be described as a mean difference with 95% CI.Ethics and disseminationEthical approval has been granted from the Women’s and Children’s Health Network Research Ethics Committee (HREC/19/WCHN/018). The results of this trial will be presented at scientific conferences and published in peer-reviewed journals.Trial registration numberACTRN12619001511123.


2003 ◽  
Vol 110 (1) ◽  
pp. 13-17 ◽  
Author(s):  
Arduino A Mangoni ◽  
Roopen Arya ◽  
Elizabeth Ford ◽  
Belinda Asonganyi ◽  
Roy A Sherwood ◽  
...  

2018 ◽  
Vol 47 (3) ◽  
pp. 928-937 ◽  
Author(s):  
Rebecca C Richmond ◽  
Gemma C Sharp ◽  
Georgia Herbert ◽  
Charlotte Atkinson ◽  
Caroline Taylor ◽  
...  

BMC Medicine ◽  
2019 ◽  
Vol 17 (1) ◽  
Author(s):  
Helene McNulty ◽  
Mark Rollins ◽  
Tony Cassidy ◽  
Aoife Caffrey ◽  
Barry Marshall ◽  
...  

Abstract Background Periconceptional folic acid prevents neural tube defects (NTDs), but it is uncertain whether there are benefits for offspring neurodevelopment arising from continued maternal folic acid supplementation beyond the first trimester. We investigated the effect of folic acid supplementation during trimesters 2 and 3 of pregnancy on cognitive performance in the child. Methods We followed up the children of mothers who had participated in a randomized controlled trial in 2006/2007 of Folic Acid Supplementation during the Second and Third Trimesters (FASSTT) and received 400 μg/d folic acid or placebo from the 14th gestational week until the end of pregnancy. Cognitive performance of children at 7 years was evaluated using the Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III) and at 3 years using the Bayley’s Scale of Infant and Toddler Development (BSITD-III). Results From a total of 119 potential mother-child pairs, 70 children completed the assessment at age 7 years, and 39 at age 3 years. At 7 years, the children of folic acid treated mothers scored significantly higher than the placebo group in word reasoning: mean 13.3 (95% CI 12.4–14.2) versus 11.9 (95% CI 11.0–12.8); p = 0.027; at 3 years, they scored significantly higher in cognition: 10.3 (95% CI 9.3–11.3) versus 9.5 (95% CI 8.8–10.2); p = 0.040. At both time points, greater proportions of children from folic acid treated mothers compared with placebo had cognitive scores above the median values of 10 (girls and boys) for the BSITD-III, and 24.5 (girls) and 21.5 (boys) for the WPPSI-III tests. When compared with a nationally representative sample of British children at 7 years, WPPSI-III test scores were higher in children from folic acid treated mothers for verbal IQ (p < 0.001), performance IQ (p = 0.035), general language (p = 0.002), and full scale IQ (p = 0.001), whereas comparison of the placebo group with British children showed smaller differences in scores for verbal IQ (p = 0.034) and full scale IQ (p = 0.017) and no differences for performance IQ or general language. Conclusions Continued folic acid supplementation in pregnancy beyond the early period recommended to prevent NTD may have beneficial effects on child cognitive development. Further randomized trials in pregnancy with follow-up in childhood are warranted. Trial registration ISRCTN ISRCTN19917787. Registered 15 May 2013.


Nutrients ◽  
2018 ◽  
Vol 10 (4) ◽  
pp. 455 ◽  
Author(s):  
Aisling Geraghty ◽  
Alexandra Sexton-Oates ◽  
Eileen O’Brien ◽  
Goiuri Alberdi ◽  
Peter Fransquet ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document